Shares of Biocon surged over 7% in early trade on January 7, following an upgrade from international brokerage Jefferies.
Biocon Stock
Biocon Stock Declines After FDA Issues Form 483
Gold Silver Reports (GSR) – Biocon Stock Declines After FDA Issues Form 483 – Shares of the Bengaluru-based pharma company fell as much as 4.5 percent, most in almost two months, to Rs 634.3. The U.S. drug regulator issued form 483 with seven observations after completing pre-approval inspection of the company’s sterile drug product manufacturing facility at Bengaluru this week, according to the company’s exchange filing. Observations are largely procedural and not critical, aiming at continuous improvement, it added.
Biocon Snaps Three-Day Gains Despite Posting Profit After 5 Quarters
Gold Silver Reports (GSR) – Biocon Snaps Three-Day Gains Despite Posting Profit After 5 Quarters – Shares of the Bangalore-based bio-pharmaceutical company fell as much as 1.8 percent, the most since April 4, to Rs 651.35 after its net profit rose for the first in five quarters.
Key earnings highlights:
🔥 Revenue up 26 percent at Rs 1,169.5 crore.
🔥 Net profit up 2 percent at Rs 130 crore.
🔥 Ebitda up 24 percent at Rs 232.5 crore.
🔥 Margin at 19.9 percent versus 20.3 percent.
Buy Biocon Stock Intraday Tips Target 1035— 1054
Buy #biocon #stock #Intraday #tips: Between 995-1005 for intraday Target 1035— 1054 @Neal_Bhai #goldsilverreports #nealbhaireports — Gold Silver Reports (@goldsilverrepor) May 10, 2017 Buy Biocon Stock Intraday Tips Target 1035— 1054 | Gold Silver Reports